ArticleInvestigational new drugs2015

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Guillermo Garcia-Manero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.